Physician profile
Matthew Ray
NPI 1699354431
$865.90
in general payments reported to CMS, 2019-2025
18 companies · $631 in 2025
The $631 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $235 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $141.42 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $104.73 | 2024-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $101.14 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $85.50 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $83.48 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $55.18 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $53.17 | 2024-2025 | Caplyta |
| Amgen INC. | $37.83 | 2025 | Otezla, Repatha |
| Antares Pharma, INC. | $35.21 | 2024-2025 | Xyosted |
| Mannkind Corporation | $35.05 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.73 | 2025 | Jardiance |
| Abbott Laboratories | $19.64 | 2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $19.49 | 2025 | Veozah |
| Amneal Pharmaceuticals LLC | $16.13 | 2025 | Unithroid |
| Sandoz INC. | $15.30 | 2025 | Hyrimoz |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $14.85 | 2025 | Gemtesa |
| Tolmar, INC. | $14.06 | 2025 | Jatenzo |
| Cequr Corporation | $13.99 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.